Table 2 Comparison of NKF and TPS groups
TPS (n = 31) | NKF (n = 47) | p | |
|---|---|---|---|
Male, n (%) | 14 (45.2) | 27 (57.5) | 0.28 |
Age, mean (SD) | 71.2 (14.5) | 68.5 (12.9) | 0.39 |
ERCP indication | |||
CBD stone, n (%) | 19 (61.3) | 20 (42.6) | 0.11 |
Pancreatic neoplasm, n (%) | 8 (25.8) | 15 (31.9) | 0.56 |
Cholangiocarcinoma, n (%) | 2 (6.5) | 2 (4.3) | 0.67 |
Others (CP, other malignancy), n (%) | 2 (6.5) | 10 (21.3) | 0.08 |
Pancreatic duct – cannulation | |||
P – cannulation < 3, n (%) | 6 (19.4) | 43 (91.5) | < 0.001 |
P – cannulation ≥3, n (%) | 16 (51.6) | 4 (8.5) | < 0.001 |
P – cannulation > 5, n (%) | 6 (19.4) | 0 (0) | 0.002 |
P – cannulation > 8, n (%) | 2 (9.7) | 0 (0) | 0.03 |
P – cannulation, median (IQR) | 4.5 (3) | 0 (0) | 0.002 |
Endoscopic finding | |||
Diverticulum, n (%) | 6 (23.1) | 4 (8.5) | 0.03 |
Deep cannulation, n (%) | |||
Success | 23 (74.2) | 39 (83.0) | 0.34 |
TPS + NKF | 3 (9.7) | ||
Failure | 4 (12.9) | 8 (17) | |
Post – cannulation procedure, n (%) | |||
EPLBD | 3 (9.7) | 5 (10.6) | 0.891 |
EPBD | 7 (22.6) | 5 (10.6) | 0.15 |
ERBD (plastic stent) | 8 (25.8) | 18 (38.3) | 0.25 |
metallic stent | 0 (0) | 6 (12.7) | 0.04 |
Lithotripsy | 14 (45.2) | 15 (31.9) | 0.236 |
PEP prophylaxis, n (%) | |||
Nil | 13 (41.9) | 34 (72.3) | 0.007 |
P - stenting | 4 (12.9) | 6 (12.8) | 0.99 |
Gabexate Mesilae | 12 (38.7) | 5 (10.6) | 0.003 |
NSAIDs | 0 | 2 (4.26) | 0.24 |
Gabexate Mesilae + NSAIDs | 5 (16.1) | 3 (6.4) | 0.17 |